{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:02:36Z","timestamp":1788850956610,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Scleroderma is an autoimmune rheumatic disorder accompanied by severe fibrosis in skin and other internal organs. During scleroderma progression, resident fibroblasts undergo activation and convert to \u03b1-smooth muscle actin (\u03b1-SMA) expressing myofibroblasts (MFBs) with increased capacity to synthesize collagens and fibrogenic components. Accordingly, MFBs are a major therapeutic target for fibrosis in scleroderma and treatment with blocking MFBs could produce anti-fibrotic effects. TLY012 is an engineered human TNF-related apoptosis-inducing ligand (TRAIL) which induces selective apoptosis in transformed cells expressing its cognate death receptors (DRs). Here we report that TLY012 selectively blocks activation of dermal fibroblasts and induces DR-mediated apoptosis in \u03b1-SMA\n                    <jats:sup>+\u00a0<\/jats:sup>\n                    MFBs through upregulated DR5 during its activation. In vivo, TLY012 reverses established skin fibrosis to near-normal skin architecture in mouse models of scleroderma. Thus, the TRAIL pathway plays a critical role in tissue remodeling and targeting upregulated DR5 in \u03b1-SMA\n                    <jats:sup>+<\/jats:sup>\n                    MFBs is a viable therapy for fibrosis in scleroderma.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-09101-4","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T06:03:45Z","timestamp":1552025025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma"],"prefix":"10.1038","volume":"10","author":[{"given":"Jong-Sung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Joo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogyi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoseong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-4159","authenticated-orcid":false,"given":"Stephanie","family":"Slania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Hummers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung-Tae","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen R.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6856-0165","authenticated-orcid":false,"given":"Harry C.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-5865","authenticated-orcid":false,"given":"Eric","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-0127","authenticated-orcid":false,"given":"Dong Hee","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangmeyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Choon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor V.","family":"Roschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"9101_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrrheum.2012.191","volume":"9","author":"ZH McMahan","year":"2013","unstructured":"McMahan, Z. H. & Hummers, L. K. Systemic sclerosis--challenges for clinical practice. Nat. Rev. Rheumatol. 9, 90\u2013100 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"9101_CR2","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","volume":"10","author":"YY Ho","year":"2014","unstructured":"Ho, Y. Y., Lagares, D., Tager, A. M. & Kapoor, M. Fibrosis--a lethal component of systemic sclerosis. Nat. Rev. Rheumatol. 10, 390\u2013402 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"9101_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42\u201354 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"9101_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrrheum.2010.102","volume":"6","author":"M Trojanowska","year":"2010","unstructured":"Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 453\u2013460 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"9101_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","volume":"180","author":"B Hinz","year":"2012","unstructured":"Hinz, B. et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340\u20131355 (2012).","journal-title":"Am. J. Pathol."},{"key":"9101_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/sj.jid.5700613","volume":"127","author":"B Hinz","year":"2007","unstructured":"Hinz, B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127, 526\u2013537 (2007).","journal-title":"J. Invest. Dermatol."},{"key":"9101_CR7","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Prim. 1, 15002 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"9101_CR8","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice, L. M. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 125, 2795\u20132807 (2015).","journal-title":"J. Clin. Invest."},{"key":"9101_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai, M. et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann. Rheum. Dis. 72, 1217\u20131220 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"9101_CR10","doi-asserted-by":"publisher","first-page":"R144","DOI":"10.1186\/ar4606","volume":"16","author":"P Fraticelli","year":"2014","unstructured":"Fraticelli, P. et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res. Ther. 16, R144 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"9101_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon, J. K. et al. Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res. Ther. 17, 213 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"9101_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/nrc2465","volume":"8","author":"RW Johnstone","year":"2008","unstructured":"Johnstone, R. W., Frew, A. J. & Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782\u2013798 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"9101_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.28432","volume":"64","author":"Y Oh","year":"2016","unstructured":"Oh, Y. et al. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells. Hepatology 64, 209\u2013223 (2016).","journal-title":"Hepatology"},{"key":"9101_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/jhep.2003.50002","volume":"37","author":"P Taimr","year":"2003","unstructured":"Taimr, P. et al. Activated stellate cells express the TRAIL receptor-2\/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37, 87\u201395 (2003).","journal-title":"Hepatology"},{"key":"9101_CR15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1535-7163.MCT-09-1076","volume":"9","author":"SY Chae","year":"2010","unstructured":"Chae, S. Y. et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther. 9, 1719\u20131729 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"9101_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","volume":"7","author":"SL Friedman","year":"2010","unstructured":"Friedman, S. L. Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7, 425\u2013436 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"9101_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).","journal-title":"Nat. Commun."},{"key":"9101_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/jid.2014.127","volume":"134","author":"ST Arron","year":"2014","unstructured":"Arron, S. T. et al. High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis. J. Invest. Dermatol. 134, 2138\u20132145 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"9101_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask, A. & Abraham, D. J. TGF-beta signaling and the fibrotic response. FASEB J. 18, 816\u2013827 (2004).","journal-title":"FASEB J."},{"key":"9101_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm.3777","volume":"21","author":"K Palumbo-Zerr","year":"2015","unstructured":"Palumbo-Zerr, K. et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis. Nat. Med. 21, 150\u2013158 (2015).","journal-title":"Nat. Med."},{"key":"9101_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka, A., Dobaczewski, M. & Frangogiannis, N. G. TGF-beta signaling in fibrosis. Growth Factors 29, 196\u2013202 (2011).","journal-title":"Growth Factors"},{"key":"9101_CR22","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1136\/gut.2005.082701","volume":"55","author":"E Novo","year":"2006","unstructured":"Novo, E. et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 55, 1174\u20131182 (2006).","journal-title":"Gut"},{"key":"9101_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biocel.2011.10.011","volume":"44","author":"JC Horowitz","year":"2012","unstructured":"Horowitz, J. C. et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int. J. Biochem. Cell. Biol. 44, 158\u2013169 (2012).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"9101_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.214","volume":"4","author":"M van Dijk","year":"2013","unstructured":"van Dijk, M., Halpin-McCormick, A., Sessler, T., Samali, A. & Szegezdi, E. Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways. Cell Death Dis. 4, e702 (2013).","journal-title":"Cell Death Dis."},{"key":"9101_CR25","first-page":"2770","volume":"59","author":"GS Wu","year":"1999","unstructured":"Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S. & El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770\u20132775 (1999).","journal-title":"Cancer Res."},{"key":"9101_CR26","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1002\/art.27647","volume":"62","author":"C Beyer","year":"2010","unstructured":"Beyer, C., Schett, G., Distler, O. & Distler, J. H. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum. 62, 2831\u20132844 (2010).","journal-title":"Arthritis Rheum."},{"key":"9101_CR27","doi-asserted-by":"publisher","first-page":"10895","DOI":"10.1073\/pnas.0802702105","volume":"105","author":"K Takeda","year":"2008","unstructured":"Takeda, K. et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc. Natl Acad. Sci. USA 105, 10895\u201310900 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9101_CR28","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.1208698109","volume":"109","author":"F Li","year":"2012","unstructured":"Li, F. & Ravetch, J. V. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proc. Natl Acad. Sci. USA 109, 10966\u201310971 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9101_CR29","doi-asserted-by":"crossref","unstructured":"Takimoto, R. & El-Deiry, W. S. Wild-type p53 transactivates the KILLER\/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19, 1735-1743 (2000).","DOI":"10.1038\/sj.onc.1203489"},{"key":"9101_CR30","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/0008-5472.CAN-04-1195","volume":"64","author":"X Liu","year":"2004","unstructured":"Liu, X., Yue, P., Khuri, F. R. & Sun, S. Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 64, 5078\u20135083 (2004).","journal-title":"Cancer Res."},{"key":"9101_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","volume":"5","author":"J Varga","year":"2009","unstructured":"Varga, J. & Pasche, B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol. 5, 200\u2013206 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"9101_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi, Y. & Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685\u2013700 (2003).","journal-title":"Cell"},{"key":"9101_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/cr.2008.328","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang, Y. E. Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128\u2013139 (2009).","journal-title":"Cell Res."},{"key":"9101_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0014-5793(01)02947-7","volume":"507","author":"T Yoshida","year":"2001","unstructured":"Yoshida, T., Maeda, A., Tani, N. & Sakai, T. Promoter structure and transcription initiation sites of the human death receptor 5\/TRAIL-R2 gene. FEBS Lett. 507, 381\u2013385 (2001).","journal-title":"FEBS Lett."},{"key":"9101_CR35","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke, J., von Karstedt, S., Zinngrebe, J. & Walczak, H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21, 1350\u20131364 (2014).","journal-title":"Cell Death Differ."},{"key":"9101_CR36","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10067-012-2023-3","volume":"31","author":"NA Azab","year":"2012","unstructured":"Azab, N. A., Rady, H. M. & Marzouk, S. A. Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin. Rheumatol. 31, 1359\u20131364 (2012).","journal-title":"Clin. Rheumatol."},{"key":"9101_CR37","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu, V. S. et al. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 19, 1047\u20131053 (2013).","journal-title":"Nat. Med."},{"key":"9101_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"9101_CR39","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1074\/jbc.M113.530303","volume":"289","author":"M Cam","year":"2014","unstructured":"Cam, M. et al. p53\/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage. J. Biol. Chem. 289, 4083\u20134094 (2014).","journal-title":"J. Biol. Chem."},{"key":"9101_CR40","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2014-207109","volume":"75","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann. Rheum. Dis. 75, 883\u2013890 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"9101_CR41","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20101629","volume":"208","author":"C Dees","year":"2011","unstructured":"Dees, C. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J. Exp. Med. 208, 961\u2013972 (2011).","journal-title":"J. Exp. Med."},{"key":"9101_CR42","doi-asserted-by":"publisher","first-page":"23ra20","DOI":"10.1126\/scitranslmed.3000488","volume":"2","author":"BL Loeys","year":"2010","unstructured":"Loeys, B. L. et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci. Transl. Med. 2, 23ra20 (2010).","journal-title":"Sci. Transl. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09101-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:17:54Z","timestamp":1671207474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-09101-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["9101"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-09101-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735291565.793557984","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]},"assertion":[{"value":"27 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.V.R. is CSO of Theraly Fibrosis Inc. and holds ownership equity in the company. J.H., M.G.P., and S.L. are co-founders of Theraly Fibrosis Inc. and hold ownership equity in the company. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1128"}}